Loading…

READY TO ROCK?

Click the button below to start exploring our website and learn more about our awesome company
Start exploring

MyMD Pharmaceuticals Enrolls First Person in Phase 2 Scientific Trial of MYMD-1 as a Treatment for Delaying Aging and Extending Healthy And Balanced Life-span

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (” MyMD” or “the Company”), a clinical stage pharmaceutical business dedicated to prolonging healthy and balanced lifespan, today revealed that the very first person has actually been signed up in the Company’s Stage 2 scientific trial of lead prospect MYMD-1, a dental immune regulatory authority medication, as a treatment for delaying aging and also broadening healthy lifespan.

The primary endpoint for the Stage 2 double-blind, placebo-controlled scientific trial is to achieve a decrease in the distributing levels of (TNF-α), growth death variable receptor I (TNFRI) and IL-6. TNF-α and also IL-6 are the proteins in the body that cause swelling and assist activate the process of aging. The secondary measures of the test will certainly be the safety and security, tolerability, as well as pharmacokinetics in this population of people.

” In a Stage 1 professional trial of MYMD-1, we showed the medicine’s statistically considerable efficiency in reducing levels of TNF-α, a key player in creating pathological aging, in the blood. The FDA has authorized TNF-α reduction as the main endpoint for our Phase 2 research study, which we believe positions us well for an effective Phase 2 end result,” said Chris Chapman, M.D., Head Of State, Director and Chief Medical Police Officer of MyMD. “The initiation of client enrollment in this research developments our goal to reduce the aging procedure, stop loss of muscle cells in aging, restriction frailty, as well as extend healthy and balanced lifespan.”

MyMD has stated that there are no FDA-approved medicines for treating aging conditions as well as extending healthy life-span people, a market anticipated to be at the very least $600 billion by 20251 according to a major investment bank. TNF-α blockers are one of the most proposed medicines by revenue, a worldwide market of around $40 billion each year,2 as well as, according to Nature Aging journal,3 a stagnation in aging that would certainly enhance life span by one year deserves $38 trillion and by ten years is worth $367 trillion.

Along with aging, MYMD-1’s distinct action in regulating the body immune system and also treating chronic swelling is being developed for the treatment of autoimmune disease, consisting of rheumatoid arthritis (RA), multiple sclerosis (MS), diabetes mellitus, and inflammatory digestive tract disease.

” We plan to start composing protocols for a Phase 2 pilot study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman kept in mind. “The increasing occurrence of rheumatoid joint inflammation and also other autoimmune and inflammatory conditions are driving demand for TNF preventions like MYMD-1, and also our team believe our by mouth carried out medication with really low poisoning would be disruptive to the $60 billion market for RA if accepted by the FDA for this sign.”

Rheumatoid arthritis influences about 40 million individuals globally.4.

Regarding MYMD-1.

Originally developed for autoimmune diseases, MYMD-1’s key purpose is to reduce the aging procedure, avoid sarcopenia and frailty, as well as expand healthy life-span. Because it can cross the blood-brain barrier and get to the central nerve system (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related disorders. Its system of action and also efficacy in illness including multiple sclerosis (MS) and also thyroiditis have actually been studied via partnerships with several scholastic organizations. MYMD-1 is also showing promise in pre-clinical research studies as a potential therapy for blog post- COVID-19 complications and also as an anti-fibrotic and anti-proliferation healing.

MYMD-1 has actually shown effectiveness in pre-clinical researches in regulating the immune system by executing as a careful prevention of growth necrosis factor-alpha (TNF-α), a vehicle driver of chronic swelling. Unlike other treatments, MYMD-1 has been shown in these pre-clinical research studies to precisely obstruct TNF-α when it comes to be overactivated in autoimmune conditions and cytokine storms, however not block it from doing its normal task of being a first -responder to any type of routine type of modest infection. MYMD-1’s simplicity of dental application is an additional differentiator compared to presently readily available TNF-α blockers, all of which require delivery by shot or infusion. No accepted TNF prevention has ever been dosed by mouth. On top of that, the medicine is not immunosuppressive and also has not been shown to cause the severe negative effects typical with typical therapies that deal with swelling.

Regarding MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical business dedicated to expanding healthy life expectancy, is concentrated on establishing two novel healing platforms that treat the causes of condition rather than just attending to the signs and symptoms. MYMD-1 is a medicine system based upon a clinical stage little molecule that manages the immune system to control TNF-α, which drives persistent inflammation, as well as other pro-inflammatory cell signaling cytokines. MYMD-1 is being established to postpone aging, rise long life, and deal with autoimmune diseases as well as COVID-19- connected anxiety. The Firm’s 2nd medicine system, Supera-CBD, is being created to deal with chronic discomfort, dependency and also epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being established to resolve as well as improve upon the swiftly expanding CBD market, that includes both FDA accepted medicines as well as CBD products not presently managed as medications. For more information, visit www.mymd.com.